A phishing attack on AI utilization-management vendor Xsolis exposed the medical and personal data of 1.4 million patients across eight U.S. health systems, including Mayo Clinic and UW Medicine.
Insilico Medicine has begun a Phase III trial of rentosertib, an AI-designed drug for idiopathic pulmonary fibrosis, marking the first AI-discovered therapy for the disease to reach late-stage testing.
Illinois, Nevada, Rhode Island and Maine now ban AI chatbots from practicing therapy outright, while Utah, California and Colorado are instead forcing chatbots to disclose they're not human — a patchwork that's reshaping how AI mental-health apps operate state by state.
Johnson & Johnson's Ottava surgical robot finally won FDA authorization in July 2026 after more than a decade of delays, entering a soft-tissue robotic surgery market suddenly crowded with new AI-guided rivals.
Eli Lilly has switched on LillyPod, a 1,016-GPU NVIDIA supercomputer delivering over 9,000 petaflops — a bet that owning frontier-scale AI compute is now essential to compete in drug discovery.
Schrodinger has co-founded Tectora Therapeutics, a $55 million Series A-backed biotech built to develop two of its own AI-designed drug candidates for immunology and inflammation.
A Nature Cancer study spanning over 125,000 mammograms found Google's AI outperformed human radiologists on sensitivity while matching them on specificity — the largest NHS test yet of AI in breast cancer screening.
Guidehealth, RediMinds and SandsRx are the first organizations to earn URAC's new Health Care AI Accreditation, a voluntary credential meant to fill the gap regulators haven't closed.
Qure.ai's qXR-Detect just won six new FDA clearances for chest X-ray findings, becoming the first such tool cleared with a plan to keep updating its algorithm without a new filing each time.
Novo Nordisk has named AWS its preferred cloud and AI partner and opened a co-innovation hub in London, using tools like Amazon Bio Discovery and Bedrock to try to compress the path from drug target to first human dose, part of a broader wave of pharma-hyperscaler AI deals.